FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus

Table 1 Baseline patient demographics n (%)

Host characteristics	All(n = 2060)	Patients with TE (n = 214)
Mean age ± SD (yr)	45.2 ± 11.4	45.7 ± 11.7
Race
Caucasian	1599 (77.6)	169 (79.0)
Black	98 (4.8)	5 (2.3)
Asian	322 (15.6)	39 (18.2)
Other	41 (2.0)	1 (0.5)
Genotype
1	1186 (57.6)	120 (56.1)
2/3	874 (42.4)	94 (43.9)
Male sex	1196 (58.1)	105 (49.1)
Mean BMI ± SD	26.6 ± 5.1	25.1 ± 4.2
ALT > 1.5 × ULN	911 (44.2)	98 (45.8)
Mean biopsy length ± SD (mm)	17.0 ± 9.1	15.8 ± 8.2
METAVIR fibrosis stage
F0	740 (35.9)	80 (37.4)
F1	942 (45.7)	91 (42.5)
F2	159 (7.7)	16 (7.5)
F3	101 (4.9)	9 (4.2)
F4	118 (5.7)	18 (8.4)
METAVIR activity
A0-1	1125 (54.6)	126 (58.9)
A2-3	935 (45.4)	88 (41.1)

ALT: Alanine transaminase; BMI: Body mass index; SD: Standard deviation; TE: Transient elastography; ULN: Upper limit of normal.

Table 2 Performance of FibroSURE and transient elastography in patients from Asia vs non-Asian regions

Test	Region (n)	F2-4 (%)	Sens	Spec	PPV (%)	NPV (%)	Accuracy (%)	AUROC
FS	Asia (253)	24.9	0.90	0.60	42.9	95.0	67.6	0.83
	NAR (1802)	17.4	0.86	0.61	31.9	95.4	65.5	0.82
TE	Asia (33)	24.2	0.88	0.92	77.8	95.8	90.9	0.92
	NAR (181)	19.3	0.77	0.87	58.7	94.1	85.1	0.87
FS + TE	Asia (33)	24.2	0.88	1.00	100.0	96.2	97.0	0.97
	NAR (176)	19.3	0.91	0.68	40.8	97.0	72.7	0.88

AUROC: Area under the receiver operating curve; FS: FibroSURE; NAR: Non-Asian region; NPV: Negative predictive value; PPV: Positive predictive value; Sens: Sensitivity; Spec: Specificity; TE: Transient elastography.